A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back for another expansion project at its flagship factory in Tianjin.

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a Strong Buy.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants ...

Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

View the latest Novo Nordisk A/S (NOVO.B) stock price, news, historical charts, analyst ratings and financial information from WSJ.

See the latest Novo Nordisk AS ADR stock price (NVO:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Get the detailed quarterly/annual income statement for Novo Nordisk A/S (NVO). Find out the revenue, expenses and profit or loss over the last fiscal year.

Danish investor Novo Holdings, the controlling shareholder of drugmaker Novo Nordisk, is evaluating buying a stake in an Indian multi-speciality hospital chain that is backed by a mid-market private ...

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they weighed on the equity fund run by the man often dubbed ‘Britain’s ...